With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.224311-51-7,2-(Di-tert-Butylphosphino)biphenyl,as a common compound, the synthetic route is as follows.
Under nitrogen atmosphere, a mixture of 4-[[4-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenyl trifluoromethanesulfonate (265 mg), palladium(II)acetate (5 mg), 2-[bis(tert-butyl)phosphino]biphenyl (12 mg), and powdered potassium phosphate (177 mg) in toluene (2.6 ml) was heated to 100¡ã C. for 10 hours.After being allowed to cool to room temperature, the mixture was concentrated and the residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give ethyl 4-[4-[[4-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]sulfonyl]phenoxy]benzoate (93 mg) as a white amorphous. NMR (CDCl3, delta): 1.36 (9H, br s), 1.40 (3H, t, J=7 Hz), 2.60-3.05 (2H, m), 3.05-3.60 (4H, m), 4.27 (1H, br s, OH), 4.38 (2H, q, J=7 Hz), 4.86 (1H, m), 6.90-7.45 (10H, m), 7.86 (2H, d, J=8 Hz), 7.90 (2H, d, J=8 Hz), 8.07 (2H, d, J=8 Hz) (+)ESI-MS (m/z): 702 (M+Na)+
224311-51-7, The synthetic route of 224311-51-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; FUJISAWA PHARMACEUTICAL CO., LTD.; US2004/106653; (2004); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate